We are live on ! Find out more
DA

DCF Advisers Portfolio holdings

AUM $375M
1-Year Est. Return 72.65%
This Fund
S&P 500
This Quarter Est. Return
-1.84%
1 Year Est. Return
+72.65%
3 Year Est. Return
+156.29%
5 Year Est. Return
+218.72%
10 Year Est. Return
–
AUM
$227M
AUM Growth
-$55.7M
Cap. Flow
-$49.7M
Cap. Flow %
-21.93%
Top 10 Hldgs %
50.08%
Holding
105
New
12
Increased
23
Reduced
19
Closed
24

Top Buys

Rank Stock Value
1
IMPL
Impel Pharmaceuticals Inc. Common Stock
IMPL
+$2.18M
2
ARGX icon
argenx
ARGX
+$1.58M
3
ALT icon
Altimmune
ALT
+$1.14M
4
AAPL icon
Apple
AAPL
+$1.1M
5
XNCR icon
Xencor
XNCR
+$1.08M

Top Sells

Rank Stock Value
1
GOOG icon
Alphabet (Google) Class C
GOOG
+$5.93M
2
KIN
Kindred Biosciences, Inc.
KIN
+$3.32M
3
ORCL icon
Oracle
ORCL
+$1.99M
4
GLD icon
SPDR Gold Trust
GLD
+$1.67M
5
AMD icon
Advanced Micro Devices
AMD
+$1.53M

Sector Composition

Rank Sector Weight
1 Healthcare 38.05%
2 Technology 12.14%
3 Communication Services 8.72%
4 Financials 5.36%
5 Consumer Discretionary 4.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
51
Amarin Corp
AMRN
$298M
$816K 0.36%
8,000
-850
-10% -$83.5K
LIT icon
52
Global X Lithium & Battery Tech ETF
LIT
$1.51B
$779K 0.34%
+9,500
New +$779K
AZN icon
53
AstraZeneca
AZN
$263B
$765K 0.34%
+6,373
New +$742K
BDX icon
54
Becton Dickinson
BDX
$45.6B
$737K 0.33%
3,075
– –
ITW icon
55
Illinois Tool Works
ITW
$82.6B
$723K 0.32%
3,500
– –
MSFT icon
56
Microsoft
MSFT
$3.45T
$705K 0.31%
2,500
– –
ADMS
57
DELISTED
Adamas Pharmaceuticals
ADMS
$687K 0.3%
140,000
– –
NXPI icon
58
NXP Semiconductors
NXPI
$57.8B
$686K 0.3%
3,500
– –
WBD icon
59
Warner Bros
WBD
$65.9B
$635K 0.28%
25,000
– –
LLY icon
60
CALL
Eli Lilly
LLY
$1.02T
$578K 0.26%
+2,500
New +$617K
BIIB icon
61
Biogen
BIIB
$30B
$566K 0.25%
2,000
+1,000
+100% +$328K
NKTR icon
62
Nektar Therapeutics
NKTR
$2.39B
$562K 0.25%
2,087
– –
TBT icon
63
ProShares Trust UltraShort Lehman 20+ Year Treasury
TBT
$304M
$551K 0.24%
+30,000
New +$526K
PARA
64
DELISTED
Paramount Global Class B
PARA
$494K 0.22%
12,500
+2,500
+25% +$102K
OVID icon
65
Ovid Therapeutics
OVID
$414M
$476K 0.21%
141,701
+2,000
+1% +$7.29K
BOX icon
66
Box
BOX
$4.37B
$438K 0.19%
18,500
-1,500
-8% -$36.8K
MU icon
67
CALL
Micron Technology
MU
$930B
$355K 0.16%
5,000
+2,500
+100% +$188K
INCY icon
68
CALL
Incyte
INCY
$24.2B
$344K 0.15%
+5,000
New +$380K
APTV icon
69
Aptiv
APTV
$12B
$335K 0.15%
2,250
– –
FCX icon
70
Freeport-McMoran
FCX
$90B
$325K 0.14%
10,000
– –
ARNA
71
DELISTED
Arena Pharmaceuticals Inc
ARNA
$298K 0.13%
5,000
– –
AIRT icon
72
Air T
AIRT
$75.5M
$277K 0.12%
9,671
+998
+12% +$31.9K
APTX
73
DELISTED
Aptinyx Inc. Common Stock
APTX
$267K 0.12%
114,000
– –
WBA
74
DELISTED
Walgreens Boots Alliance
WBA
$235K 0.1%
+5,000
New +$241K
LCTX icon
75
Lineage Cell Therapeutics
LCTX
$269M
$219K 0.1%
87,000
+12,500
+17% +$32.1K
1 2
3
4 5

Similar funds

JIC
JRM Investment Counsel Omaha, Nebraska $375M AUM 13.43% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
AIM
Access Investment Management Atlanta, Georgia $376M AUM 17.2% 1-Year Est. Return
MWM
McMill Wealth Management Norfolk, Nebraska $376M AUM 14.46% 1-Year Est. Return
RCP
RIT Capital Partners London, United Kingdom $374M AUM 25.18% 1-Year Est. Return
HPM
Helix Partners Management New York $374M AUM 136.73% 1-Year Est. Return
CAG
Compass Advisory Group Melville, New York $374M AUM 14.59% 1-Year Est. Return
LWMNY
Landmark Wealth Management (New York) Melville, New York $373M AUM 12.01% 1-Year Est. Return

DCF Advisers's Q3 2021 Portfolio in Review

As of Q3 2021, DCF Advisers held 105 positions worth $227M, down 20% from $282M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

DCF Advisers withdrew a net $49.7M in Q3 2021, closing 24 positions and reducing 19 holdings. Its most notable exit was Kindred Biosciences, Inc., an estimated $3.32M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 29% a quarter earlier, followed by Technology and Communication Services.

Against the trend, DCF Advisers opened a new position in Impel Pharmaceuticals Inc. Common Stock worth $1.83M.

  • DCF Advisers's largest Q3 2021 buy was Impel Pharmaceuticals Inc. Common Stock: 150,000 shares worth $1.83M.
  • DCF Advisers added most to argenx in Q3 2021, an estimated $1.58M increase.
  • DCF Advisers's biggest Q3 2021 reduction was Alphabet (Google) Class C, cutting an estimated $5.93M.
  • DCF Advisers fully exited Kindred Biosciences, Inc. in Q3 2021, selling an estimated $3.32M.
  • DCF Advisers's ten largest holdings make up 50% of its $227M portfolio in Q3 2021.
  • DCF Advisers opened 12 new positions and closed 24 in Q3 2021.
  • DCF Advisers's portfolio value fell 20% quarter-over-quarter to $227M.

Based on DCF Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.